<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02398825</url>
  </required_header>
  <id_info>
    <org_study_id>CML1315</org_study_id>
    <secondary_id>2015-001102-34</secondary_id>
    <nct_id>NCT02398825</nct_id>
  </id_info>
  <brief_title>Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib</brief_title>
  <official_title>Optimizing Ponatinib USe (OPUS). A GIMEMA Phase 2 Study of the Activity and Risk Profile of Ponatinib, 30 mg Once Daily, in Chronic Myeloid Leukemia (CML) Chronic Phase (CP) Patients Resistant to Imatinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at evaluating the efficacy of treatment with ponatinib in patients with&#xD;
      chronic myeloid leukemia who are in a chronic phase and who previously received treatment&#xD;
      with imatinib but resulted to be resistant to it.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 2, single-arm, multicentre, open label. No interim analysis is planned, but a&#xD;
      monitoring committee will evaluate the data every 6 months. Ponatinib is given orally 30 mg&#xD;
      daily, with dose adjustment to 15 mg daily once a BCR-ABL1 level smaller or equal to 0.1%&#xD;
      (MMR) has been achieved and confirmed in the next test, 4 weeks apart. A return to prior, 30&#xD;
      mg, dose is due in case of return of BCR-ABL1 transcripts level to &gt; 1%. Dose adjustments for&#xD;
      toxicity are detailed in the protocol. Treatment time will be 52 weeks, during which study&#xD;
      drug will be provided free-of-charge by ARIAD Pharmaceuticals, upon approval of the protocol.&#xD;
      Treatment is discontinued at any time in case of failure or treatment-related SAEs. After one&#xD;
      year of treatment, upon request of the local investigator and upon confirmation of the&#xD;
      Treatment Advisory Committee (TAC, see section 23), ARIAD Pharmaceutics, Inc. will continue&#xD;
      to provide ponatinib for the study patients who will benefit from treatment continuation, for&#xD;
      at least 2 years, until the drug will be approved with that indication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 23, 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with major cytogenetic response</measure>
    <time_frame>After 52 weeks of ponatinib treatment start</time_frame>
    <description>Cytogenetic response (CyR) is defined based on the percentage of Ph pos metaphases, as evaluated by chromosome banding analysis (CBA) of at least 20 marrow cell metaphases:&#xD;
Major Cytogenetic Response if Ph pos metaphases &lt; 35%&#xD;
Complete (CCyR) if Ph pos metaphases 0 or FISH BCR-ABL1 nuclei minor or equal to 1%&#xD;
Partial (PCyR) if Ph pos metaphases 1-34%&#xD;
Minor (mCyR) if Ph pos metaphases 35-65%&#xD;
Minimal or none (min/none CyR) if Ph pos metaphases &gt; 65% If marrow cell metaphases cannot be obtained or analysed, interphase fluorescence-in-situ-hybridization (FISH) can be used, but only to distinguish a CCyR (minor or equal to 1% positive nuclei out of at least 200 nuclei) from a non CCyR. FISH data cannot be used to classify a response as minimal, minor, or partial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Cardiovascular Adverse Events (AEs)</measure>
    <time_frame>After three years from ponatinib treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of blood hypertension AEs</measure>
    <time_frame>After three years from ponatinib treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of pancreatitis AEs</measure>
    <time_frame>After three years from ponatinib treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients achieving Complete Cytogenetic Response (CCyR)</measure>
    <time_frame>After 52 weeks of ponatinib treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients achieving major molecular response</measure>
    <time_frame>After 52 weeks of ponatinib treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with failure-free survival</measure>
    <time_frame>At 36 months from ponatinib treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with progression-free survival</measure>
    <time_frame>At 36 months from ponatinib treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients in overal survival</measure>
    <time_frame>At 36 months from ponatinib treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients in event-free survival</measure>
    <time_frame>At 36 months from ponatinib treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life patterns over time with the EORTC QLQ-C30 and the EORTC QLQ-CML24 questionnaires</measure>
    <time_frame>At baseline and at at weeks 4, 12, 24, 36 and 52</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <condition>Chronic Phase</condition>
  <condition>Adults</condition>
  <arm_group>
    <arm_group_label>Ponatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ponatinib</intervention_name>
    <description>Ponatinib is given orally 30 mg daily, with dose adjustment to 15 mg daily once a BCR-ABL1 level minor or equal to 0.1% (MMR) has been achieved and confirmed in the next test, 4 weeks apart. A return to prior, 30 mg, dose is due in case of return of BCR-ABL1 transcripts level to &gt; 1%. Dose adjustments for toxicity are detailed in the protocol.</description>
    <arm_group_label>Ponatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Cytogenetic and/or molecular confirmed diagnosis of Ph+ and/or BCR-ABL1+ CML&#xD;
&#xD;
          2. Age â‰¥ 18 years&#xD;
&#xD;
          3. Chronic phase CML&#xD;
&#xD;
          4. Prior treatment with imatinib, any dose&#xD;
&#xD;
          5. Resistance to imatinib, as defined by any one of the ELN 2013 failure criteria, as&#xD;
             follows:&#xD;
&#xD;
               -  no complete hematologic response (CHR) at 3 months&#xD;
&#xD;
               -  no cytogenetic response (CyR) (Ph+ &gt; 95%) at 3 months&#xD;
&#xD;
               -  Less than partial CyR (PCyR, Ph+ &gt; 35%) at 6 months&#xD;
&#xD;
               -  BCR-ABL1 &gt; 10% at 6 months&#xD;
&#xD;
               -  Non complete CyR (CCyR) (Ph+ &gt; 0%) at 12 months&#xD;
&#xD;
               -  BCR-ABL1 &gt; 1% at 12 months&#xD;
&#xD;
               -  Loss of CHR, at any time&#xD;
&#xD;
               -  Loss of CCyR, at any time&#xD;
&#xD;
               -  Confirmed loss of major molecular response (MMR) (BCR-ABL1 bigger or equal to&#xD;
                  0.1% in two consecutive tests, of which one bigger or equal to 1%), at any time&#xD;
&#xD;
               -  Any new BCR-ABL1 mutation, at any time&#xD;
&#xD;
          6. For females of childbearing potential, a negative pregnancy test must be documented&#xD;
             prior to enrolment&#xD;
&#xD;
          7. An effective form of contraception with their sexual partners from enrolment through 4&#xD;
             months after the end of treatment&#xD;
&#xD;
          8. Signed written informed consent according to ICH/EU/GCP and national local laws prior&#xD;
             to any study procedures&#xD;
&#xD;
          9. Willingness and ability to comply with scheduled visits and study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Accelerated or blastic phase CML&#xD;
&#xD;
          2. Patients previously treated with nilotinib or dasatinib&#xD;
&#xD;
          3. Patients with the T315I mutation&#xD;
&#xD;
          4. History of acute pancreatitis within 1 year of study or history of chronic&#xD;
             pancreatitis or of alcohol abuse&#xD;
&#xD;
          5. Patients with history of acute myocardial infarction (AMI), unstable angina or&#xD;
             coronary heart disease (CHD), congestive heart failure, cerebrovascular events (CVE)&#xD;
             (stroke or transitory ischemic attack), or peripheral artery occlusive disease (PAOD)&#xD;
&#xD;
          6. Compelled to take medications that are known to be associated with Torsades de Pointes&#xD;
             and/or with significant QTc prolongation&#xD;
&#xD;
          7. Pregnant or breastfeeding&#xD;
&#xD;
          8. Any condition or illness that, in the opinion of the Investigator, would compromise&#xD;
             patient safety or interfere with the evaluation of the drug&#xD;
&#xD;
          9. Lack of informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fausto Castagnetti</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Hematology, S. Orsola-Malpighi University of Bologna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aos Ss. Antonio E Biagio E C. Arrigo - Soc Ematologia</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Di Bologna Policlinico S. Orsola - Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asst Degli Spedali Civili Di Brescia - Uo Ematologia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ao Brotzu, Presidio Ospedaliero A. Businco - Sc Ematologia E Ctmo</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ctc U.O Di Ematologia Con Trapianto Di Midollo Osseo</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ  di Catania - Cattedra di Ematologia - Ospedale &quot;Ferrarotto&quot;</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ao Di Catanzaro &quot;Pugliese-Ciaccio&quot;, Presidio Ospedaliero &quot;Ciaccio - de Lellis&quot; - Ematologia</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aou Arcispedale Sant'Anna - Cona (Fe) - Uoc Ematologia E Fisiopatologia Della Coagulazione</name>
      <address>
        <city>Cona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aso S. Croce E Carle - Cuneo - Sc Ematologia</name>
      <address>
        <city>Cuneo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Aou San Martino - Genova - Uo Clinica Ematologica</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asl Lecce, Ospedale 'V. Fazzi' - Uo Ematologia</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>.R.S.T. Srl Irccs - Meldola - Sc Oncologia Medica</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aou Policlinico &quot;G. Martino&quot; - Messina - Uoc Ematologia</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC Oncoematologia- Padiglione Marcora 2Â° piano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Ospedale S. Raffaele - Milano - Uo Oncoematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milano UnitÃ  Trapianto di Midollo Ist. Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ao Di Rilievo Nazionale Antonio Cardarelli - Napoli - Uoc Ematologia Con Trapianto Di Midollo</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aou Federico Ii - Napoli - Uoc Ematologia</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aou San Luigi Gonzaga - Orbassano - Scdu Ematologia Generale E Oncoematologia</name>
      <address>
        <city>Orbassano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ao Ospedali Riuniti Villa Sofia Cervello - Palermo - Uo Ematologia Con Utmo</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aou Policlinico P. Giaccone - Palermo - Uo Ematologia</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Ircss Policlinico San Matteo - Pavia - Uo Ematologia</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asl Pescara, Presidio Ospedaliero 'Spirito Santo' - Uoc Ematologia Clinica</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UnitÃ  Operativa Ematologia e Centro Trapianti - Dipartimento di Oncologia ed Ematologia - AUSL Ospedale G. da Saliceto</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aou Pisana - Uo Ematologia Universitaria</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ausl Della Romagna, Ospedale &quot;Santa Maria Delle Croci&quot; - Ravenna - Ematologia</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ausl Della Romagna, Ospedale &quot;Infermi&quot; - Rimini - Uo Ematologia</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ao San Camillo Forlanini - Roma - Uoc Ematologia E Trapianto Cellule Staminali</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asl Roma 2, Ospedale S. Eugenio- Ospedale S.Eugenio - Uoc Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roma Uoc Pronto Soccorso E Accettazione Ematologica - Dipartimento Biotecnologie Cellulari Ed Ematologia - UniversitÃ  Degli Studi Di Roma &quot;Sapienza&quot;</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ente Ecclesiastico Casa Sollievo Della Sofferenza - San Giovanni Rotondo - Ematologia</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aou Senese - Uoc Ematologia E Trapianti</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ao S. Maria - Terni - Sc Onco Ematologia</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UnitÃ  Operativa Di Ematologia - Presidio Ospedaliero Di Treviso - Azienda Ulss N.2 Marca Trevigiana</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aou Integrata Di Verona, Policlinico G.B. Rossi - Uoc Ematologia</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aulss 8 Berica - Ospedale Di Vicenza - Uoc Ematologia</name>
      <address>
        <city>Vicenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.gimema.it</url>
    <description>GIMEMA Foundation</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 15, 2015</study_first_submitted>
  <study_first_submitted_qc>March 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2015</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic myeloid leukemia</keyword>
  <keyword>Chronic phase</keyword>
  <keyword>Adults</keyword>
  <keyword>Ponatinib</keyword>
  <keyword>Imatinib resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ponatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

